Schizophrenia affects approximately 685,000 people in the UK. Despite decades of antipsychotic treatment, many patients experience persistent symptoms, significant side effects, and reduced quality of life. A new era of clinical trials is emerging — with novel mechanisms targeting glutamate, muscarinic, and inflammatory pathways, plus a renewed focus on cognitive symptoms, early intervention, and personalised treatment approaches.
The UK has a strong tradition in psychiatric clinical trials, with specialist early intervention services, academic health science centres, and the NIHR Mental Health Translational Research Collaboration driving innovation. The Maudsley Hospital in London, the National Institute for Health and Care Excellence (NICE) guidelines, and the Royal College of Psychiatrists all contribute to a research-ready environment.
Currently, there are over 80 actively recruiting schizophrenia trials in the UK. The most exciting development is the arrival of muscarinic receptor agonists — the first genuinely novel antipsychotic mechanism in decades — alongside advances in long-acting injectable formulations, digital therapeutics, and precision psychiatry.
Types of Schizophrenia Trials
Novel Antipsychotics
Muscarinic agonists (xanomeline/trospium), TAAR1 agonists, and glutamate modulators targeting symptoms that current medications do not adequately address.
Long-Acting Injectables
Extended-duration LAI antipsychotics (6-monthly, annual) to improve adherence and reduce relapse. A major focus for NHS implementation.
Early Intervention
Treating first-episode psychosis aggressively to improve long-term outcomes, including duration of untreated psychosis reduction trials.
Cognitive and Digital
Cognitive remediation therapy, digital therapeutics, virtual reality social skills training, and neurostimulation for cognitive and negative symptoms.
Muscarinic Agonists: The New Frontier
The most significant development in schizophrenia treatment in a generation is the emergence of muscarinic receptor agonists. Unlike traditional antipsychotics that target dopamine receptors, these drugs activate M1 and M4 muscarinic receptors in the brain:
Xanomeline/trospium chloride (Cobenfy) — the first approved muscarinic agonist for schizophrenia. Xanomeline activates M1/M4 receptors (antipsychotic effect) while trospium blocks peripheral muscarinic receptors (reducing side effects). UK trials are exploring its use in broader populations and as an adjunct to existing treatment
Next-generation muscarinic agonists — more selective M1 and M4 agonists in development, aiming for even better efficacy with fewer side effects
Combination with D2 agents — trials testing whether muscarinic agonists can enhance the effect of existing antipsychotics, allowing dose reduction
Muscarinic agonists are particularly promising because they appear to address negative symptoms (social withdrawal, lack of motivation) and cognitive impairment — areas where current antipsychotics are largely ineffective.
Novel Antipsychotic Mechanisms
Beyond muscarinic agonists, several other novel mechanisms are in UK trials:
TAAR1 agonists (ulotaront) — targeting trace amine-associated receptor 1, which modulates dopamine, serotonin, and glutamate without D2 receptor blockade
Glutamate modulators — targeting NMDA receptor hypofunction, a leading theory of schizophrenia pathophysiology
Anti-inflammatory approaches — minocycline, aspirin, and targeted anti-cytokine therapies addressing the inflammatory component of schizophrenia
Cannabinoid-based therapies — CBD and novel cannabinoid formulations as adjunctive treatments
Oxytocin — intranasal oxytocin for negative symptoms and social cognition deficits
Long-Acting Injectable Formulations
Medication non-adherence is the leading cause of relapse in schizophrenia. Long-acting injectable (LAI) antipsychotics, given by injection every 2–12 weeks, eliminate the need for daily pills. UK trials are pushing the boundaries:
6-monthly and annual LAIs — paliperidone and aripiprazole formulations that need only one or two injections per year
LAI for first-episode psychosis — offering LAIs early in the disease course rather than as a last resort
Patient preference studies — shared decision-making frameworks for LAI versus oral treatment
New molecule LAIs — long-acting formulations of newer antipsychotics like cariprazine and brexpiprazole
Early Intervention and First-Episode Psychosis
Research increasingly shows that the first 5 years after psychosis onset — the "critical period" — determine long-term outcomes. UK trials are leading the way in early intervention:
Duration of untreated psychosis (DUP) reduction — community-based programmes to identify and treat psychosis faster
Treatment minimisation in first-episode — trials testing whether lower antipsychotic doses can be effective in early psychosis, reducing long-term side effects
Prodromal intervention — treating people at clinical high risk for psychosis to prevent or delay onset
Recovery-focused approaches — combining medication with psychological therapies, vocational support, and family interventions
Cognitive and Negative Symptom Trials
Cognitive impairment (memory, attention, executive function) and negative symptoms (lack of motivation, social withdrawal, flat affect) are the biggest unmet needs in schizophrenia treatment. UK trials include:
Cognitive remediation therapy (CRT) — computer-based cognitive training programmes, now being tested in large-scale UK trials
Virtual reality social cognition training — immersive VR environments to practice social interactions and improve social functioning
Transcranial magnetic stimulation (TMS) — targeting cognitive and negative symptoms through brain stimulation
Digital therapeutics — smartphone-based cognitive remediation and medication management apps being validated in NHS settings
Who Can Participate?
Common eligibility criteria for UK schizophrenia trials include:
Confirmed diagnosis of schizophrenia or schizoaffective disorder by a psychiatrist
Disease duration — some trials target first-episode (within 2 years of diagnosis), others chronic (>2 years)
Symptom severity — measured by PANSS (Positive and Negative Syndrome Scale), often requiring a minimum score
Current medication status — some trials require stable antipsychotic treatment; others accept medication-free patients
Capacity to consent — understanding the trial procedures and voluntarily agreeing to participate
Age requirements — typically 18–65 for adult trials
Support system — many trials require a care coordinator or family member to support participation
💡 Tip: Involve Your Care Team Early
Schizophrenia trials often require input from your care coordinator, community psychiatric nurse, or psychiatrist. Discuss your interest in research with your care team — they can help identify suitable trials and provide the clinical information trial teams need. Many NHS trusts have research teams that proactively match patients to studies.
UK Schizophrenia Trial Locations
Major UK centres running schizophrenia trials include:
London — Maudsley Hospital, Institute of Psychiatry (King's College London), St Pancras, Queen Mary
Manchester — Manchester University NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust
Cambridge — Cambridgeshire and Peterborough NHS Foundation Trust, University of Cambridge Department of Psychiatry
Oxford — Oxford Health NHS Foundation Trust, University of Oxford Department of Psychiatry
Birmingham — Birmingham Women's and Children's NHS Foundation Trust, Forward Thinking Birmingham
Glasgow — NHS Greater Glasgow and Clyde, University of Glasgow Institute of Health and Wellbeing
Cardiff — Cardiff and Vale University Health Board, Cardiff University MRC Centre for Neuropsychiatric Genetics
Newcastle — Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle University
How to Find Your Match
Use our Smart Matcher to find schizophrenia trials tailored to your diagnosis, symptom profile, and treatment history. Whether you are interested in novel medications, long-acting injectables, or cognitive therapies, we can help you find actively recruiting studies.